Literature DB >> 10593369

Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors.

R S Legro1, P Blanche, R M Krauss, R A Lobo.   

Abstract

OBJECTIVE: To examine the influence of hyperandrogenism on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclass levels as well as lipoprotein (a) levels in hyperandrogenic women compared with a control group.
DESIGN: Case-control study.
SETTING: University-based outpatient clinic. PATIENT(S): Sixteen Hispanic women with polycystic ovary syndrome were compared with 21 controls matched for age, weight, and ethnicity. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Fasting serum levels of testosterone, insulin, and lipoproteins. RESULT(S): Compared with controls, women with polycystic ovary syndrome had significantly lower levels of apolipoprotein A-I (95+/-28 mg/dL versus 144+/-42 mg/dL) and HDL2a (30.9%+/-4.4% versus 36.6%+/-5.4%) but significantly higher levels of HDL3c (5.1%+/-2.2% versus 2.4%+/-1.5%). There were no statistically significant differences in LDL subclasses between groups, but there was a high incidence (54%) of the atherogenic lipoprotein phenotype B in this Hispanic population. As a group, Hispanic women with the abnormal B phenotype had significantly higher levels of insulin, HDL, HDL2b, and triglycerides. CONCLUSION(S): Hyperandrogenemia may have an adverse effect on serum lipoproteins through effects on HDL subclasses. Hispanic women may have a higher incidence of the atherogenic lipoprotein phenotype B, which may increase their risk for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593369     DOI: 10.1016/s0015-0282(99)00401-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

2.  Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk.

Authors:  E Gourgari; M Lodish; R Shamburek; M Keil; R Wesley; M Walter; M Sampson; S Bernstein; D Khurana; C Lyssikatos; S Ten; A Dobs; A T Remaley; C A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-09-15       Impact factor: 5.958

3.  Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.

Authors:  O Celik; O Acbay
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 4.256

Review 4.  Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review.

Authors:  Holly R Harris; Kathryn L Terry
Journal:  Fertil Res Pract       Date:  2016-12-05

Review 5.  Cardiometabolic aspects of polycystic ovarian syndrome.

Authors:  Li Wei Cho; Harpal S Randeva; Stephen L Atkin
Journal:  Vasc Health Risk Manag       Date:  2007

Review 6.  Dyslipidemia in women with polycystic ovary syndrome.

Authors:  Jin Ju Kim; Young Min Choi
Journal:  Obstet Gynecol Sci       Date:  2013-05-16

Review 7.  Epidemiology, diagnosis, and management of polycystic ovary syndrome.

Authors:  Susan M Sirmans; Kristen A Pate
Journal:  Clin Epidemiol       Date:  2013-12-18       Impact factor: 4.790

8.  Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study.

Authors:  Jeng-Hsiu Hung; Li-Yu Hu; Shih-Jen Tsai; Albert C Yang; Min-Wei Huang; Pan-Ming Chen; Shu-Li Wang; Ti Lu; Cheng-Che Shen
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.